Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of pyrotinib in previously treated advanced or metastatic biliary tract cancer
CTR20210929Phase 2Terminated
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in biliary cancer, sponsored by Hengrui Therapeutics. Started Apr 2021; status: terminated.
02
Drugs
pyrotinib
03
Conditions
biliary cancer
Beyond the preview
Go deeper on CTR20210929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210929.